SHELTON, CT / ACCESSWIRE / October 25, 2019 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), is a development stage nano-biopharmaceutical Company focused on countering viral infections, which has developed a unique, proprietary nanomedicine technology. The Company is developing nanoviricide drug candidates against several commercially important viral diseases: seasonal and potentially-epidemic influenzas, bird flu, HIV/AIDS, cold sores and genital herpes infection, viral eye diseases, as well as dengue viruses.
SHELTON, CT / ACCESSWIRE / October 9, 2019 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in nanomedicines with novel platform technology to treat difficult and life-threatening viral diseases, announces that it has initiated bio-analytical studies as part of the required IND-enabling preclinical safety and toxicology studies of NV-HHV-101, moving towards human clinical trials. The Company has contracted NorthEast BioLab, Hamden CT, to conduct the bio-analytical studies and facilitate the toxicokinetic analyses. NorthEast BioLab has already performed the bio-analytical assay development and validation and is in the process of determining the concentrations of NV-HHV-101 in blood samples from the general safety and toxicology studies that are required for IND.
SHELTON, CT / ACCESSWIRE / October 3, 2019 / NanoViricides, Inc., (NYSE American:NNVC) (the "Company"), a leader in developing novel nanomedicines to treat viral diseases, based on the nanoviricides® platform, announces that Anil R. Diwan, PhD, President and Executive Chairman, was interviewed by broadcast journalist Christine Corrado of Proactive Investors, a leading multi-media news organization, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt, and London. The Company recently announced that its first clinical drug candidate, NV-HHV-101, for the treatment of the Shingles virus (aka VZV), is on track with required preclinical GLP Safety and Toxicology studies moving towards human clinical trials.
SHELTON, CT / ACCESSWIRE / September 30, 2019 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), announced today that it has filed a Form S-1 Registration Statement with the Securities and Exchange Commission ("SEC"). This Form S-1 will enable the Company to raise the necessary capital once it is declared effective by the SEC. Maxim Group LLC will serve as the Company's underwriter for the offering under this Form S-1.